Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype

被引:36
|
作者
Hillen, Nina [1 ]
Mester, Gabor [1 ]
Lemmel, Claudia [1 ]
Weinzierl, Andreas O. [1 ]
Mueller, Margret [1 ]
Wernet, Dorothee [2 ]
Hennenlotter, Joerg [3 ]
Stenzl, Arnulf [3 ]
Rammensee, Hans-Georg [1 ]
Stevanovic, Stefan [1 ,4 ]
机构
[1] Univ Tubingen, Dept Immunol, Tubingen, Germany
[2] Univ Tubingen, Dept Transfus Med, Tubingen, Germany
[3] Univ Tubingen, Dept Urol, Tubingen, Germany
[4] Proteom Ctr Tubingen, Tubingen, Germany
关键词
Antigen presentation/processing; CD8 T cells; Immunotherapy; Mass spectrometry; MHC;
D O I
10.1002/eji.200838632
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human leukocyte antigens (HLA) have long been grouped into supertypes to facilitate peptide-based immunotherapy. Analysis of several hundreds of peptides presented by all nine antigens of the HLA-B44 supertype (HLA-B*18, B*37, B*40, B*41, B*44, B*45, B*47, B*49 and B*50) revealed unique peptide motifs for each of them. Taking all supertype members into consideration only 25 out of 670 natural ligands were found on more than one HLA molecule. Further direct comparisons by two mass spectrometric methods - isotope labeling as well as a label-free approach - consistently demonstrated only minute overlaps of below 3% between the ligandomes of different HLA antigens. In addition, T cell reactions of healthy donors against immunodominant HLA-B*44 and HLA-B*40 epitopes from EBV lacked promiscuous T-cell recognition within the HLA-B44 supertype. Taken together, these results challenge the common paradigm of broadly presented epitopes within this supertype.
引用
收藏
页码:2993 / 3003
页数:11
相关论文
共 50 条
  • [1] Definition of the HLA-B44 supertype from natural ligand repertoires
    不详
    IMMUNOBIOLOGY, 2005, 210 (6-8) : 547 - 547
  • [2] A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition
    Macdonald, WA
    Purcell, AW
    Misfud, NA
    Ely, LK
    Williams, DS
    Chang, LN
    Gorman, J
    Clements, CS
    Kjer-Nielsen, L
    Koelle, DM
    Burrows, SR
    Tait, BD
    Holdsworth, R
    Brooks, AG
    Lovrecz, GO
    Lu, L
    Rossjohn, J
    McCluskey, J
    JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (05): : 679 - 691
  • [3] A prospective cohort study of HLA-B44 supertype as predictor of response to novel immune checkpoint combinations.
    Hernandez-Guerrero, Tatiana
    Doger, Bernard
    Morillo, Daniel
    Casado, Victoria
    Domine, Manuel
    Garcia Foncillas, Jesus
    Moreno, Victor
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Simultaneous prediction of binding capacity for multiple molecules of the HLA B44 supertype
    Sidney, J
    Southwood, S
    Pasquetto, V
    Sette, A
    JOURNAL OF IMMUNOLOGY, 2003, 171 (11): : 5964 - 5974
  • [5] Differences between HLA-B44 and HLA-B60 in patients with smear-positive pulmonary tuberculosis and exposed controls
    Bothamley, GH
    JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (04): : 1051 - 1052
  • [6] SEROLOGIC RECOGNITION OF A HLA-B44(12) SUBGROUP ASSOCIATED WITH THE 44.2 SPECIFICITY DEFINED BY CML
    HEISE, ER
    TEKOLF, WA
    HAMPTON, JP
    HUMAN IMMUNOLOGY, 1984, 11 (03) : 163 - 171
  • [7] A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18
    Bilsborough, J
    Panichelli, C
    Duffour, MT
    Warnier, G
    Lurquin, C
    Schultz, ES
    Thielemans, K
    Corthals, J
    Boon, T
    van der Bruggen, P
    TISSUE ANTIGENS, 2002, 60 (01): : 16 - 24
  • [8] Lack of recognition of HLA class I mismatches outside α1/α2 domains by CD8+ alloreactive T lymphocytes: the HLA-B44 paradigm
    Bettens, F.
    Schanz, U.
    Tiercy, J-M
    TISSUE ANTIGENS, 2013, 81 (06): : 414 - 418
  • [9] A durable response to programmed cell death 1 blockade in a multidrug-resistant recurrent ovarian cancer patient with HLA-B44 supertype: A case report
    Luo, Xukai
    Sun, Yating
    Li, Jiajia
    Jiang, Qidi
    Yuan, Lei
    Li, Ting
    Chen, Mo
    Yao, Liangqing
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [10] A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes
    Brichard, VG
    Herman, J
    VanPel, A
    Wildmann, C
    Gaugler, B
    Wolfel, T
    Boon, T
    Lethe, B
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (01) : 224 - 230